Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHB-204 in Pulmonary MAC Disease
NCT04616924Phase 3Terminated
- Sponsor
- RedHill Biopharma
- Start
- Dec 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Mycobacterium avium complex lung infection comparing RHB-204 with Placebo (2 arms). Primary endpoints: Sputum culture conversion (SCC) at 6 months and Quality of Life Questionnaire - Bronchiectasis (QoL-B) Respiratory Symptoms domain score at 6 months. Started Dec 2020; status: terminated.
02
Drugs
rifabutin + clarithromycin + clofazimine
03
Conditions
Mycobacterium avium complex lung infection
Beyond the preview
Go deeper on NCT04616924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616924.